Allianz Asset Management Gmb H Revance Therapeutics, Inc. Transaction History

Allianz Asset Management Gmb H

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 13, 2019	SELL	$15.4 - $20.39 $1.09 Million - $1.44 Million	-70,621 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$18.06 - $24.96 $266,493 - $368,309	-14,756 Reduced 17.28%	70,621 $1.42 Million
Q3 2018 Nov 13, 2018	BUY	$23.55 - $30.1 $148,624 - $189,961	6,311 Added 7.98%	85,377 $2.12 Million
Q2 2018 Aug 13, 2018	SELL	$27.45 - $33.35 $10,183 - $12,372	-371 Reduced 0.47%	79,066 $2.17 Million
Q1 2018 May 14, 2018	BUY	$29.15 - $37.4 $328,549 - $421,535	11,271 Added 16.53%	79,437 $2.45 Million
Q4 2017 Feb 13, 2018	BUY	$24.55 - $36.3 $253,945 - $375,487	10,344 Added 17.89%	68,166 $2.44 Million
Q3 2017 Nov 13, 2017	BUY	$22.55 - $28.1 $34,659 - $43,189	1,537 Added 2.73%	57,822 $1.59 Million
Q2 2017 Aug 14, 2017	BUY	N/A	5,672 Added 11.21%	56,285 $1.49 Million
Q1 2017 Apr 17, 2019	BUY	N/A	50,613	50,613 $1.05 Million

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

Stay updated on Allianz Asset Management Gmb H with notifications on news.